Genomics Startup Mesh Bio Receives Series A Funding of IDR 55 Billion Led by East Ventures

Startups deep tech Singapore-based healthcare company Mesh Bio announced that it has raised Series A funding of $3,5 million (around IDR 55,3 billion) led by East Ventures. Elev8, Seeds Capital, and several other investors participated in the round.

Previously, East Ventures also injected an undisclosed amount of funds into Mesh Bio in October 2023. Previous funding rounds include a $1,8 million seed funding round in October 2021. The company was founded in 2018 by Andrew Wu (Co-Founder and CEO) and Arsen Batagov (Co-Founder and CTO).

Mesh Bio will use this fresh funding to offer technology digital twin or digital twins to healthcare providers, as well as expanding the application of these solutions in Hong Kong and Southeast Asia, especially in Indonesia and the Philippines.

In the Philippines, the company has obtained regulatory approval and is conducting trials implementing one of the technologies digital twin those with the public health system in Singapore that signal great opportunities in improving the health outcomes of patients with chronic diseases.

In October 2023, Mesh Bio received approval from the Health Sciences Authority (HSA) to market HealthVector® Diabetes as medical device software. HealthVector® Diabetes is currently in the trial implementation phase in several hospitals, including: Singapore General Hospital (SGH), Tan Tock Seng Hospital (TTSH), as well as several selected polyclinics for potential clinical application.

“We are pleased to announce the close of Mesh Bio's series A funding round. "This important step empowers us to expand digital health solutions for chronic disease management in Southeast Asia," said Mesh Bio Co-Founder and CEO Andrew Wu in an official statement, Tuesday (30/1).

Bio Mesh Products

Wu continued, Southeast Asia has many unmet healthcare needs, and Mesh Bio's focus is to effectively address these gaps.

The high prevalence of chronic diseases, ranging from diabetes to heart disease in Southeast Asia has encouraged more general practitioners who lack specialist training in endocrinology to treat patients with chronic diseases.

Mesh Bio provides advanced digital solutions to assist healthcare providers in patient management. Mesh Bio solutions provide patient data and predictive analytics that equip doctors with information and diagnoses about their patients and the diseases they suffer from.

One of the products is the DARA® Health Intelligence Platform, enabling data-based service delivery thereby improving patient engagement and health. Based on this data, DARA provides predictive analysis to identify patients at risk of chronic disease so they can receive earlier diagnosis and treatment.

Additionally, the platform also enables physicians to gain and utilize knowledge from a global community of healthcare practitioners in line with best clinical practices and guidelines, as well as holistic patient assessment.

It is stated that DARA has been used by more than 120 health centers in Singapore, Malaysia and Indonesia for preventive health checks. Not only that, Mesh Bio has expanded its platform for chronic disease management through HealthVector® Diabetes.

“We are pleased to continue supporting Mesh Bio. In today's rapidly evolving healthcare landscape, Mesh Bio is emerging to offer its leading technology designed to revolutionize patient care. Their innovative approach to leveraging predictive analytics is groundbreaking, enabling more personalized and preventative healthcare. We look forward to further collaboration in transforming healthcare systems in Southeast Asia and beyond," said Co-Founder and Managing Partner of East Ventures Willson Cuaca.